American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
China said on Saturday it strongly opposes Washington's decision to levy additional tariffs on $550 billion worth of Chinese goods and warned the United States of consequences...Politicsread more
Evercore ISI analyst Mark Schoenebaum was just named Institutional Investor's top sell-side analyst for large, mid and small cap stocks in the health care sector.
Overall, Schoenebaum remains bullish on the sector and is not worried about the recent weakness. Instead, he attributed the selloff to a simple "repositioning" from growth oriented, generalist portfolios.
"I call them biotourists," Schoenebaum told CNBC's "Power Lunch" on Wednesday. "These are the same investors who threw in the towel and returned to the sector after avoiding it for years."
Schoenebaum's favorite biotech stock is Gilead Science which develops treatments for cardiovascular, liver, respiratory and HIV/AIDs. He maintains a price target of $115 on the stock, in part because of what he calls their "fantastic" management team.
BioMarin Pharmaceuticals, which develops products to treat for serious burns and muscular dystrophy, is another favorite, in anticipation of a possible FDA approval later this year.
Year to date, BioMarin is up 44.5 percent, and outperformed the broader market by nearly 50 percent. Schoenebaum projects an additional ten percent climb for the stock.
Long-term, he's bullish on Biogen, which makes therapies for people living with neurological, autoimmune and hematologic disorders.
"It makes a lot of sense here. The upside-downside ratio is 5:1 over a two year period."
Schoenebaum thinks both stocks will return a minimum ten percent by the first quarter of 2016.
Evercore ISI expects to receive or intends to seek compensation for investment banking services from AbbVie within the next three months
Neither Schoenebaum, his family nor Evercore ISI have conflicts with Pfizer, BioMarin or Gilead Science.
CNBC's Michael Bloom contributed to this article